News | September 17, 2010

Delivery system enables repositioning of aortic aneurysm stent grafts

September 17, 2010 - Clinical uses will soon begin for the C3 Delivery System for the Gore Excluder Device as a minimally invasive treatment for patients suffering from an abdominal aortic aneurysm (AAA). The delivery system, made by W.L. Gore & Associates, provides surgeons with cannulation options and allows them to bring the contralateral gate to the contralateral guidewire.

Dr. Eric Verhoeven, Chief, Department of Vascular and Endovascular Surgery, at Klinikum Süd in Nürnberg, Germany, performed the first procedure to treat a patient with an abdominal aortic aneurysm (AAA) using the new system. Additional procedures were performed subsequently by Dr. Piotr Kasprzak, Leader of Vascular Surgery, at Klinikum der Universität in Regensburg, Germany and Dr. Hans-Joachim Florek, Chief of Vascular Surgery, at Elbe-Weißeritztal Kliniken in Dresden (Freital), Germany.

Once delivered into the aorta, the Gore C3 Delivery System enables repositioning of the stent graft. The ability to reposition the device can minimize complications that could occur if the graft is positioned incorrectly during the initial deployment.

“We specifically selected our initial patients with short or angulated necks, or with difficult iliac anatomy, to be able to use the graft to its full extent," Verhoeven said. "In the four patients treated with the Gore C3 Delivery System, we repositioned the graft twice for level and for rotational orientation, to maximize the sealing zone in the aortic neck and facilitate cannulation of the contralateral limb. In the other two patients repositioning was unnecessary because either the proximal position was perfect after the initial deployment, or cannulation was immediately successful. However, having the option to reposition the Gore Excluder Device enabled us to treat these challenging anatomies with added confidence during our initial deployment. Overall, the Gore C3 Delivery System worked as it was designed and provided unparalleled control while remaining intuitive and easy to use.”

More than 100,000 Gore Excluder Devices have been implanted in patients worldwide since 1997. The Gore Excluder AAA Endoprosthesis is constructed of a durable ePTFE bifurcated graft with an outer self-expanding nitinol support structure which provides both device flexibility and material durability. The function of the endoprosthesis is to internally reline the abdominal aorta, including the bifurcation, and isolate the aneurysm from blood circulation. The device is inserted by a catheter-based delivery technique through small incisions in the patient’s legs.

For more information:

Related Content

FDA Grants Breakthrough Device Designation for Valiant Thoracoabdominal Aortic Aneurysm Stent Graft
News | Stent Grafts | October 09, 2019
Medtronic plc announced it has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA...
PQ Bypass Granted IDE Approval to Start TORUS SFA Stent Graft Pivotal Study
News | Stent Grafts | October 08, 2019
PQ Bypass Inc. announced it has received full approval of its investigational device exemption (IDE) trial of the...
First U.S. Patient Receives Gore Tag Conformable Thoracic Stent Graft With Active Control
News | Stent Grafts | July 10, 2019
W. L. Gore & Associates Inc. (Gore) announced the first U.S. implant of the Gore Tag Conformable Thoracic Stent...
Gore Receives FDA Approval for Gore Tag Conformable Thoracic Stent Graft
Technology | Stent Grafts | May 15, 2019
W. L. Gore & Associates Inc. (Gore) announced the U.S. Food and Drug Administration (FDA) has granted regulatory...
Aortic Stent Graft Global Market to Reach $5.4 Billion by 2028
News | Stent Grafts | February 14, 2019
Abdominal aortic stent grafts will remain the largest segment in the global aortic stent graft market at least through...
Medtronic Receives FDA Approval for Valiant Navion Thoracic Stent Graft System
Technology | Stent Grafts | February 07, 2019
Medtronic plc recently received U.S. Food and Drug Administration (FDA) approval for the Valiant Navion thoracic stent...
Endologix Ends Unrestricted Sales and Use of Nellix System
News | Stent Grafts | January 07, 2019
January 7, 2019 — Endologix Inc.
Endologix Reports Positive One-Year Results From the Ovation LUCY Study
News | Stent Grafts | July 16, 2018
Endologix Inc. announced one-year results from the LUCY (Evaluation of FemaLes who are Underrepresented Candidates for...
FDA Committee Votes in Favor of Incraft AAA Stent Graft System
News | Stent Grafts | June 13, 2018
Cardinal Health announced that its Incraft Abdominal Aortic Aneurysm (AAA) Stent Graft System has received a favorable...
First Patient Enrolled in Gore Excluder Investigational Study
News | Stent Grafts | January 08, 2018
January 8, 2018 — W. L. Gore & Associates Inc.